Castle Biosciences, Inc. products

Predicting Individual Risk of Recurrence or Metastasis: DecisionDx-Melanoma was designed to address the need for a more accurate predictor of metastatic risk in patients diagnosed with cutaneous (skin) melanoma.

Increased Clarity for Difficult-to-Diagnose Melanocytic Lesions. MyPath Melanoma and DecisionDx DiffDx Melanoma gene expression profile (GEP) tests are designed to provide objective information to aid in the diagnosis and inform management decisions for patients with ambiguous melanocytic lesions.

Our DecisionDx-CMSeq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue.  The test includes hotspot mutations in the genes BRAF, NRAS and KIT.

Predicting Individual Risk of Metastasis: DecisionDx-SCC is now commercially available. DecisionDx-SCC is clinically validated as a significant predictor of metastasis and the strongest predictor of risk compared to traditional clinical and pathological factors. DecisionDx-SCC complements traditional prognostic risk assessment factors, enabling more informed choices about treatment and follow-up care.

Uveal melanoma, commonly known as ocular or choroidal melanoma, is a rare cancer of the eye with approximately 2,000 patients diagnosed annually in the U.S. At the time of initial diagnosis, approximately 97% of patients are free of metastasis.  However, within five years, approximately 30% of patients will develop metastasis – rising to nearly 50% in the following years.

Our DecisionDx-UMSeq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma.  Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as possible about a uveal melanoma tumor from a single biopsy. To provide additional genetic information from your biopsy, Castle Biosciences offers an optional gene sequencing panel that can find mutations in seven important genes in your uveal melanoma tumor.

Castle Biosciences offers DecisionDx-PRAME gene expression profile testing to assess expression of the PRAME (preferentially expressed antigen in melanoma) gene. DecisionDx-PRAME is an optional, additional test that can be run on the same sample as your DecisionDx^®-UM GEP (gene expression profile) test.

Our platform combines a unique approach to bring together all the key elements of biologically aware artificial intelligence (AI) to deliver the spatialomics revolution to the clinician and enable individualized, patient-centric decision-making.